|
|
|
|
European Biopharmaceutical Review |
| |
|
European Biopharmaceutical Review (EBR) is a journal designed to fill a unique
position in scientific publishing. Published quarterly, it provides a dedicated platform
of communication and information for the European biopharmaceutical market across Europe, North America, and the rest of the world.
With editorial consisting of in-depth articles, case studies, meetings, and report
reviews written by specialists with hands-on experience in the biopharma industry; traditional multi-national pharma companies; investment houses; and industry-associated governmental, economic, and societal bodies. Each quarterly edition examines topical areas of importance across the board of biopharmaceutical
research and development, with regular feature sections on BioBusiness
Development, Research and Innovation, BioDiscovery, BioManufacturing
plus special focusses on geographic or therapeutic territories.
Connect with us on Twitter: follow @EBRmagazine
Read
our publications on the go in the Samedan app for phones and tablets. You
can download issues for offline reading, and our archives go as far back
as 2008! Download for free on the App Store, GooglePlay, or Amazon.   
|
|
|
|
|
|
Widgets Magazine
Widgets Magazine
Widgets Magazine
 |
Industry Events |
 |
World Advanced Therapies & Regenerative Medicine Congress 2019
15-17 May 2019, Business Design Centre, London
The World Advanced Therapies & Regenerative
Medicine Congress is an exhibition and conference that has grown to become one
of the best and most established cell and gene events in the world today.
The 2019 edition will be in its 14th year and it continues to grow and attract
a large audience of biotech, pharma, start-ups, investors, research and
technology companies from around the world. The conference and exhibition will
host over 1000 attendees, 250 speakers and 80 exhibition booths. Over 500
different global companies are represented every year at this event.
More info >> |
|
 |
News and Press Releases |
 |
Clinical and Regulatory Operational Excellence Forum
1. Innovative technologies are expected to take clinical development, licensing, and other regulatory processes to the next level in the future. What do you see are the biggest challenges facing companies when trying to cope with continued data growth in a fast changing environment?
Pharmaceutical companies are heavily regulated and introducing change needs proof of acceptance by the authorities. The chance that authorities do not agree with that change makes the industry risk averse. Changes in a stable GxP environment are almost by default seen as a risk, however, not adapting to new technologies should also be seen as a risk! Therefore, ICH developed the ICH Q8, Q9, Q10, Q11, and Q12 guidelines, to anticipate change and implement changes much faster, with less of a regulatory burden. Nevertheless, industry is not picking up with the desired pace. Why not?
More info >> |
|
 |
White Papers |
 |
|
High-tech Packaging for High-tech Medicine
West Pharmaceutical Services, Inc.
As more biologics and biosimilars come on to the global pharmaceutical market, they can and will present unique packaging and containment challenges. For materials that are sensitive to glass or that may require larger-dose volumes or custom configurations, cyclic olefin polymers may offer a solution. These novel materials for drug container closure systems can provide a needed alternative to traditional glass containment systems for advanced therapeutics.
More info >> |
|
|
